Lobbying client

VAXART INC.

Vaccine development

The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 3 of its records are shown together here.

Filings
28
Filed by
3
Reported in-house
—
Reported by firms
$1,220,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2020 to 2026

Filings

28 filings, newest first.
Filing Filed by Amount
3rd Quarter - Report
3rd Quarter 2026
TODD STRATEGY GROUP $60,000 reported
2nd Quarter - Report
2nd Quarter 2026
TODD STRATEGY GROUP $60,000 reported
1st Quarter - Report
1st Quarter 2026
TODD STRATEGY GROUP $60,000 reported
4th Quarter - Report
4th Quarter 2025
TODD STRATEGY GROUP $50,000 reported
3rd Quarter - Report
3rd Quarter 2025
TODD STRATEGY GROUP $50,000 reported
2nd Quarter - Report
2nd Quarter 2025
TODD STRATEGY GROUP $50,000 reported
Registration
2nd Quarter 2025
TODD STRATEGY GROUP — reported
4th Quarter - Termination
4th Quarter 2022
JEFFREY J. KIMBELL & ASSOCIATES, INC. $20,000 reported
4th Quarter - Termination
4th Quarter 2022
RICCHETTI INCORPORATED $80,000 reported
3rd Quarter - Report
3rd Quarter 2022
JEFFREY J. KIMBELL & ASSOCIATES, INC. $20,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
RICCHETTI INCORPORATED 9 $690,000
TODD STRATEGY GROUP 6 $330,000
JEFFREY J. KIMBELL & ASSOCIATES, INC. 10 $200,000

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Medical/Disease Research/Clinical Labs MED 17
Health Issues HCR 11

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.